[Translation] A single-center, open-label, randomized, two-formulation, two-sequence, two-period, two-cycle, two-crossover human bioequivalence trial of melogabalin besylate tablets administered orally to Chinese participants under fasting and postprandial conditions.
研究健康试验参与者空腹及餐后单次口服受试制剂苯磺酸美洛加巴林片(大连美创药业有限公司,规格:5mg)与参比制剂苯磺酸美洛加巴林片(商品名:Tarlige®,DAIICHI SANKYO CO., LTD.,规格:5mg)在吸收程度和速度方面是否存在差异,评价受试制剂和参比制剂在空腹及餐后状态下给药时的生物等效性,观察受试制剂和参比制剂在健康试验参与者中的安全性。
[Translation] This study investigates whether there are differences in the absorption rate and extent between the test formulation merogabaline besylate tablets (Dalian Meichuang Pharmaceutical Co., Ltd., specification: 5mg) and the reference formulation merogabaline besylate tablets (trade name: Tarlige®, DAIICHI SANKYO CO., LTD., specification: 5mg) administered orally once in fasting and postprandial states in healthy trial participants. It also evaluates the bioequivalence of the test and reference formulations under fasting and postprandial administration and observes their safety in healthy trial participants.